BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Holdings Increased by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. increased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 23.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,317 shares of the biotechnology company’s stock after purchasing an additional 9,820 shares during the quarter. E Fund Management Co. Ltd.’s holdings in BioCryst Pharmaceuticals were worth $307,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in BCRX. Bank of New York Mellon Corp increased its position in shares of BioCryst Pharmaceuticals by 1.1% in the third quarter. Bank of New York Mellon Corp now owns 767,571 shares of the biotechnology company’s stock worth $5,434,000 after acquiring an additional 8,087 shares in the last quarter. Arete Wealth Advisors LLC increased its position in shares of BioCryst Pharmaceuticals by 64.7% in the third quarter. Arete Wealth Advisors LLC now owns 23,300 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 9,150 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of BioCryst Pharmaceuticals by 96.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 2,388 shares in the last quarter. Fifth Third Bancorp increased its position in shares of BioCryst Pharmaceuticals by 17,500.0% in the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 3,500 shares in the last quarter. Finally, Panagora Asset Management Inc. increased its position in shares of BioCryst Pharmaceuticals by 6.1% in the third quarter. Panagora Asset Management Inc. now owns 727,480 shares of the biotechnology company’s stock worth $5,151,000 after acquiring an additional 41,971 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Stock Up 4.7 %

BCRX stock traded up $0.24 during trading hours on Thursday, hitting $5.34. The company’s stock had a trading volume of 3,336,303 shares, compared to its average volume of 3,399,351. The company has a market capitalization of $1.10 billion, a PE ratio of -4.83 and a beta of 1.96. BioCryst Pharmaceuticals, Inc. has a 12 month low of $4.03 and a 12 month high of $8.96. The stock has a 50 day moving average price of $4.89 and a two-hundred day moving average price of $5.45.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06. The business had revenue of $92.80 million during the quarter, compared to the consensus estimate of $85.62 million. The business’s revenue was up 34.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.28) earnings per share. Sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.69 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. JMP Securities lifted their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “market outperform” rating in a research report on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $14.00.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.